NASDAQ: INTSIntensity Therapeutics Inc Stock
$3.21-0.16 (-4.75%)
Updated Oct 1, 2026
INTS Price
$3.21
Fair Value Price
$8.71
Market Cap
$10.48M
52 Week Low
$3.21
52 Week High
$43.50
P/E
-0.82x
P/B
1.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$9M
Beta
-0.09
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
INTS Overview
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INTS's potential to beat the market
- INTS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INTS
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.84 | A | |
| $8.21 | A | |
| $39.57 | A |
Be the first to know about important INTS news, forecast changes, insider trades & much more!
INTS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INTS ($3.21) is undervalued by 63.14% relative to our estimate of its Fair Value price of $8.71 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
INTS ($3.21) is significantly undervalued by 63.14% relative to our estimate of its Fair Value price of $8.71 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
INTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INTS due diligence checks available for Premium users.
Valuation
INTS fair value
Fair Value of INTS stock based on Discounted Cash Flow (DCF)
Price
$3.21
Fair Value
$8.71
Undervalued by
63.14%
INTS ($3.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INTS ($3.21) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.82x
Industry
8.71x
Market
48.27x
INTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
5.13x
INTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INTS's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
INTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.5M
Liabilities
$2.3M
Debt to equity
0.25
INTS's short-term assets ($11.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INTS's short-term assets ($11.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$1.6M
INTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INTS vs Biotech Stocks
Intensity Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.